Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value

$29.95+0.50 (+1.70%)

Close on Oct 29, 2026Market cap $170.71BP/E 39.4Yield 5.74%

Earnings

Pfizer's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 3, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$15.03B

+2.3% on a year earlier

Adjusted Diluted EPS, Q2 FY2026

$0.77

$0.78 a year earlier

Latest guidance

Raised

Aug 4, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Pfizer's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 28, 2026	Nov 3, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 28, 2026	Aug 4, 2026before the open	$15.03B	+2.3%	-$0.04	$0.77	Release
Q1 FY2026ended Mar 29, 2026	May 5, 2026before the open	$14.50B	+5.8%	$0.47	$0.75	Release
Q4 FY2025ended Dec 31, 2025	Feb 3, 2026before the open	$17.60B	-1.1%	-$0.29	$0.66	Release
Q3 FY2025ended Sep 28, 2025	Nov 4, 2025before the open	$16.70B	-5.6%	$0.62	$0.87	Release
Q2 FY2025ended Jun 29, 2025	Aug 5, 2025before the open	$14.70B	+10.5%	$0.51	$0.78	Release
Q1 FY2025ended Mar 30, 2025	Apr 29, 2025before the open	$13.70B	-8.1%	$0.52	$0.92	Release
Q4 FY2024ended Dec 31, 2024	Feb 4, 2025before the open	$17.80B	+25.4%	$0.07	$0.63	Release
Q3 FY2024ended Sep 29, 2024	Oct 29, 2024before the open	$17.70B	+34.1%	$0.78	$1.06	Release
Q2 FY2024ended Jun 30, 2024	Jul 30, 2024before the open	$13.30B	+4.7%	$0.01	$0.60	Release
Q1 FY2024ended Mar 31, 2024	May 1, 2024before the open	$14.90B	-18.6%	$0.55	$0.82	Release
Q4 FY2023ended Dec 31, 2023	Jan 30, 2024before the open	$14.20B	-41.6%	-$0.60	$0.10	Release
Q3 FY2023ended Oct 1, 2023	Oct 31, 2023before the open	$13.20B	-41.6%	-$0.42	-$0.17	Release
Q2 FY2023ended Jul 2, 2023	Aug 1, 2023before the open	$12.70B	-54.2%	$0.41	$0.67	Release
Q1 FY2023ended Apr 2, 2023	May 2, 2023before the open	$18.30B	-28.8%	$0.97	$1.23	Release
Q4 FY2022ended Dec 31, 2022	Jan 31, 2023before the open	$24.30B	+2.1%	$0.87	$1.14	Release
Q3 FY2022ended Oct 2, 2022	Nov 1, 2022before the open	$22.60B	-6.2%	$1.51	$1.78	Release
Q2 FY2022ended Jul 3, 2022	Jul 28, 2022before the open	$27.70B	–	$1.73	$2.04	Release
Q1 FY2022ended Apr 3, 2022	May 3, 2022before the open	$25.70B	–	$1.37	$1.62	Release
Q4 FY2021ended Dec 31, 2021	Feb 8, 2022before the open	$23.80B	–	$0.59	$1.08	Release
Q3 FY2021ended Oct 3, 2021	Nov 2, 2021before the open	$24.10B	–	$1.42	$1.34	Release
Q2 FY2021ended Jul 4, 2021	Jul 28, 2021before the open	–	–	–	–	Filing
Q1 FY2021ended Apr 4, 2021	May 4, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 2, 2021before the open	–	–	–	–	Filing
Q3 FY2020ended Sep 27, 2020	Oct 27, 2020before the open	–	–	–	–	Filing
Q2 FY2020ended Jun 28, 2020	Jul 28, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Pfizer's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Revenue	FY2026	$60.50B – $62.50B	$59.50B – $62.50B	Raised	Aug 4, 2026
Adjusted (3) diluted EPSnon-GAAP	FY2026	$2.80 – $3.00	$2.80 – $3.00	Reaffirmed	Aug 4, 2026
Adjusted (3) R&D Expensesnon-GAAP	FY2026	$10.50B – $11.50B	$10.50B – $11.50B	Lowered	Aug 4, 2026
Adjusted (3) SI&A Expensesnon-GAAP	FY2026	$12.50B – $13.50B	$12.50B – $13.50B	Raised	Aug 4, 2026
Effective Tax Rate on Adjusted (3) Incomenon-GAAP	FY2026	15%	15%	Reaffirmed	Aug 4, 2026

Guidance vs results

The last range Pfizer gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Adjusted Diluted EPS	$3.00 – $3.15	$3.23Σ4Q	Above range
FY2025	Revenue	$61.00B – $64.00B	$62.70BΣ4Q	Within range

Guidance history

Every forecast Pfizer put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 4, 2026	Adjusted (3) diluted EPS	FY2026	$2.80 – $3.00	Reaffirmed
Aug 4, 2026	Effective Tax Rate on Adjusted (3) Income	FY2026	15%	Reaffirmed
Aug 4, 2026	Adjusted (3) SI&A Expenses	FY2026	$12.50B – $13.50B	Raised
Aug 4, 2026	Adjusted (3) R&D Expenses	FY2026	$10.50B – $11.50B	Lowered
Aug 4, 2026	Revenue	FY2026	$60.50B – $62.50B	Raised
May 5, 2026	Adjusted (4) Diluted EPS	FY2026	$2.80 – $3.00	Reaffirmed
May 5, 2026	Effective Tax Rate on Adjusted (4) Income	FY2026	15%	Reaffirmed
May 5, 2026	Adjusted (4) SI&A Expenses	FY2026	$12.50B – $13.50B	Raised
May 5, 2026	Adjusted (4) R&D Expenses	FY2026	$10.50B – $11.50B	Lowered
May 5, 2026	Revenues	FY2026	$59.50B – $62.50B	Reaffirmed
Feb 3, 2026	Adjusted (3) Diluted EPS	FY2026	$2.80 – $3.00	New
Feb 3, 2026	Effective Tax Rate on Adjusted (3) Income	FY2026	15%	New
Feb 3, 2026	Adjusted (3) SI&A Expenses	FY2026	$12.50B – $13.50B	New
Feb 3, 2026	Adjusted (3) R&D Expenses	FY2026	$10.50B – $11.50B	Lowered
Feb 3, 2026	Revenues	FY2026	$59.50B – $62.50B	New
Nov 4, 2025	Adjusted Diluted EPS	FY2025	$3.00 – $3.15	Raised
Nov 4, 2025	Effective Tax Rate on Adjusted Income	FY2025	11%	Lowered
Nov 4, 2025	Adjusted SI&A Expenses	FY2025	$13.10B – $14.10B	Raised
Nov 4, 2025	Adjusted R&D Expenses	FY2025	$10.00B – $11.00B	Lowered
Nov 4, 2025	Revenues	FY2025	$61.00B – $64.00B	Reaffirmed
Aug 5, 2025	Adjusted (2) Diluted EPS	FY2025	$2.90 – $3.10	New
Aug 5, 2025	Effective Tax Rate on Adjusted (2) Income	FY2025	13%	New
Aug 5, 2025	Adjusted (2) SI&A Expenses	FY2025	$13.10B – $14.10B	New
Aug 5, 2025	Adjusted (2) R&D Expenses	FY2025	$10.40B – $11.40B	Lowered
Aug 5, 2025	Revenues	FY2025	$61.00B – $64.00B	New
Apr 29, 2025	Adjusted Diluted EPS	FY2025	$2.80 – $3.00	Reaffirmed
Apr 29, 2025	Revenues	FY2025	$61.00B – $64.00B	New
Feb 4, 2025	Adjusted Diluted EPS	FY2025	$2.80 – $3.00	New
Feb 4, 2025	Effective Tax Rate on Adjusted Income	FY2025	15%	New
Feb 4, 2025	Adjusted SI&A Expenses	FY2025	$13.30B – $14.30B	New
Feb 4, 2025	Adjusted R&D Expenses	FY2025	$10.70B – $11.70B	Lowered
Feb 4, 2025	Revenues	FY2025	$61.00B – $64.00B	New
Oct 29, 2024	Adjusted Diluted EPS	FY2024	$2.75 – $2.95	Raised
Oct 29, 2024	operational revenue growth	FY2024	+9% – +11%	New
Oct 29, 2024	Revenues	FY2024	$61.00B – $64.00B	New
Jul 30, 2024	Adjusted (2) diluted EPS guidance	FY2024	$2.45 – $2.65	Raised
Jul 30, 2024	Effective Tax Rate on Adjusted (2) Income	FY2024	13%	Lowered
Jul 30, 2024	Adjusted (2) SI&A Expenses	FY2024	$13.80B – $14.80B	Raised
Jul 30, 2024	Adjusted (2) R&D Expenses	FY2024	$11.00B – $12.00B	Lowered
Jul 30, 2024	operational revenue growth	FY2024	+9% – +11%	New
Jul 30, 2024	revenue guidance	FY2024	$59.50B – $62.50B	Raised
May 1, 2024	Adjusted (3) Diluted EPS	FY2024	$2.15 – $2.35	Raised
May 1, 2024	Effective Tax Rate on Adjusted (3) Income	FY2024	15%	New
May 1, 2024	Adjusted (3) SI&A Expenses	FY2024	$13.80B – $14.80B	New
May 1, 2024	Adjusted (3) R&D Expenses	FY2024	$11.00B – $12.00B	Lowered
May 1, 2024	Revenues	FY2024	$58.50B – $61.50B	Reaffirmed
Jan 30, 2024	Adjusted (3) diluted EPS	FY2024	$2.05 – $2.25	New
Jan 30, 2024	revenues	FY2024	$58.50B – $61.50B	New
Oct 31, 2023	Adjusted (3) diluted EPS	FY2023	$1.45 – $1.65	Lowered
Oct 31, 2023	Revenues	FY2023	$58.00B – $61.00B	Lowered
Aug 1, 2023	Adjusted diluted EPS	FY2023	$3.25 – $3.45	Reaffirmed
Aug 1, 2023	Adjusted Cost of Sales as a Percentage of Revenues	FY2023	28% – 30%	Raised
Aug 1, 2023	Effective Tax Rate on Adjusted Income	FY2023	15%	Lowered
Aug 1, 2023	Acquired IPR&D Expenses	FY2023	$100.00M	Reaffirmed
Aug 1, 2023	Adjusted SI&A Expenses	FY2023	$13.80B – $14.80B	Raised
Aug 1, 2023	Adjusted R&D Expenses	FY2023	$12.40B – $13.40B	Lowered
Aug 1, 2023	Adjusted Other (Income)/Deductions	FY2023	$1.50B	Lowered
Aug 1, 2023	Revenues	FY2023	$67.00B – $70.00B	Lowered
Aug 1, 2023	operational revenue growth	FY2023	+6% – +8%	New
May 2, 2023	Adjusted Diluted EPS	FY2023	$3.25 – $3.45	Reaffirmed
May 2, 2023	Adjusted Cost of Sales as a Percentage of Revenues	FY2023	28% – 30%	New
May 2, 2023	Effective Tax Rate on Adjusted Income	FY2023	15%	Lowered
May 2, 2023	Acquired IPR&D Expenses	FY2023	$100.00M	New
May 2, 2023	Adjusted SI&A Expenses	FY2023	$13.80B – $14.80B	New
May 2, 2023	Adjusted R&D Expenses	FY2023	$12.40B – $13.40B	Lowered
May 2, 2023	Adjusted Other (Income)/Deductions	FY2023	$1.50B	Lowered
May 2, 2023	Revenues	FY2023	$67.00B – $71.00B	Reaffirmed
Jan 31, 2023	Adjusted Diluted EPS Guidance	FY2023	$3.25 – $3.45	New
Jan 31, 2023	Revenue Guidance	FY2023	$67.00B – $71.00B	New
Nov 1, 2022	Adjusted Diluted EPS	FY2022	$6.40 – $6.50	Raised
Nov 1, 2022	Revenues	FY2022	$99.50B – $102.00B	Raised
Jul 28, 2022	Adjusted Diluted EPS	FY2022	$6.30 – $6.45	Raised
Jul 28, 2022	Revenues	FY2022	$98.00B – $102.00B	Reaffirmed
May 3, 2022	Adjusted Diluted EPS	FY2022	$6.25 – $6.45	Lowered
May 3, 2022	Adjusted Cost of Sales as a Percentage of Revenues	FY2022	32% – 34%	New
May 3, 2022	Effective Tax Rate on Adjusted Income	FY2022	16%	Lowered
May 3, 2022	Acquired IPR&D Expenses	FY2022	$900.00M	New
May 3, 2022	Adjusted SI&A Expenses	FY2022	$12.50B – $13.50B	New
May 3, 2022	Adjusted R&D Expenses	FY2022	$11.00B – $12.00B	Lowered
May 3, 2022	Adjusted Other (Income)/Deductions	FY2022	$1.90B	Lowered
May 3, 2022	Revenues	FY2022	$98.00B – $102.00B	Reaffirmed
Feb 8, 2022	Adjusted Diluted EPS	FY2022	$6.35 – $6.55	New
Feb 8, 2022	Revenues	FY2022	$98.00B – $102.00B	New
Nov 2, 2021	Adjusted Diluted EPS	FY2021	$4.13 – $4.18	New
Nov 2, 2021	Revenues	FY2021	$81.00B – $82.00B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.